Liquidia Technologies, Inc. (LQDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
LQDA POWR Grades
- Growth is the dimension where LQDA ranks best; there it ranks ahead of 64.08% of US stocks.
- The strongest trend for LQDA is in Value, which has been heading up over the past 31 weeks.
- LQDA ranks lowest in Quality; there it ranks in the 6th percentile.
LQDA Stock Summary
- With a price/sales ratio of 36.16, Liquidia Corp has a higher such ratio than 93.08% of stocks in our set.
- Revenue growth over the past 12 months for Liquidia Corp comes in at -52.64%, a number that bests only 6.3% of the US stocks we're tracking.
- Liquidia Corp's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -47.27%, greater than the shareholder yield of just 4.77% of stocks in our set.
- Stocks that are quantitatively similar to LQDA, based on their financial statements, market capitalization, and price volatility, are AYLA, FTK, KERN, NBRV, and NSPR.
- LQDA's SEC filings can be seen here. And to visit Liquidia Corp's official web site, go to www.liquidia.com.
LQDA Stock Price Chart Interactive Chart >
LQDA Price/Volume Stats
|Current price||$2.63||52-week high||$12.10|
|Prev. close||$2.68||52-week low||$2.34|
|Day high||$2.70||Avg. volume||972,347|
|50-day MA||$2.78||Dividend yield||N/A|
|200-day MA||$3.34||Market Cap||136.69M|
Liquidia Technologies, Inc. (LQDA) Company Bio
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. The company was founded in 2004 and is based in Morrisville, North Carolina.
LQDA Latest News Stream
|Loading, please wait...|
LQDA Latest Social Stream
View Full LQDA Social Stream
Latest LQDA News From Around the Web
Below are the latest news stories about Liquidia Corp that investors may wish to consider to help them evaluate LQDA as an investment opportunity.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. (a subsidiary of Liquidia Corporation, Nasdaq: LQDA) and a former United Therapeutics employee who later joined Liquidia as an executive. The claims allege that Liquidia conspired with the former employee to misappropriate United Therapeutics' trade secrets, including regulatory submissions and detailed financial forecasts, in
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH). The FDA confirmed that the resubmission was a complete, class 2 response to the previous action letter issued on November 24, 2020. The FDA set a PDUFA goal date of November 7, 2021. If the FDA det
MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare Conference. The presentation will take place on Wednesday, June 2, 2021, from 2:30 to 2:55 p.m. Eastern Daylight Time and can be accessed via a live webcast on the Liquidia website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation can be accessed for 90 days following the event. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension...
Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration
Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenousMORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of Remodulin®, is now also available for subcutaneous (“SC”) administration to treat patients diagnosed with pulmonary arterial hypertension (“PAH”). Sandoz Treprostinil Injection was the first fully-substitutable AP rated generic version of Remodulin. Both options for intravenous and SC administration of Sandoz generic Treprostinil Injection are now available at the same specialty pharmacy that dispenses the brand name medicine. On May 21, 2021, Liquidia PAH’s manufacturing partner, Chengdu ...
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -5.00% and 260.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
LQDA Price Returns
Continue Researching LQDAWant to see what other sources are saying about Liquidia Technologies Inc's financials and stock price? Try the links below:
Liquidia Technologies Inc (LQDA) Stock Price | Nasdaq
Liquidia Technologies Inc (LQDA) Stock Quote, History and News - Yahoo Finance
Liquidia Technologies Inc (LQDA) Stock Price and Basic Information | MarketWatch